Yet another exciting news about our RAG1-SCID trial! To improve the recruitment, we included an additional clinical site to the trial (outside RECOMB): Kayseri Hospital, Turkey. This center has now obtained ethical approval and the trial is open to treat patients there as well! Congratulations!